Table 3.
Treatments, Complications, and Clinical Outcomes of 584 COVID-19 Patients
| Variables | Total (n = 584) | Diabetes (n = 84) | Nondiabetes (n = 500) | P Value |
|---|---|---|---|---|
| Treatments | ||||
| Antiviral treatment | 435/584 (74.5%) | 54 /84 (64.3%) | 381/500 (76.2%) | .030 |
| Antibiotics | 418/584 (71.6%) | 63/84 (75.0%) | 355/500 (71.0%) | .514 |
| Traditional Chinese medicine | 380/584 (65.1%) | 52/84 (61.9%) | 328/500 (65.6%) | .537 |
| Corticosteroids | 175/584 (29.9%) | 35/84 (41.7%) | 140/500 (28.0%) | .014 |
| Intravenous immunoglobin | 107/584 (18.3%) | 23/84 (27.4%) | 84/500 (16.8%) | .032 |
| Mechanical ventilation | 57/584 (9.8%) | 14/84 (16.7%) | 43/500 (8.6%) | .028 |
| ICU admission | 38/584 (6.5%) | 9/84 (10.7%) | 29/500 (5.8%) | .097 |
| Complications | ||||
| Respiratory failure | 152/583 (26.1%) | 31/84 (36.9%) | 121/499 (24.2%) | .022 |
| Acute cardiac injury | 120/480 (25.0%) | 33/70 (47.4%) | 87/410 (21.2%) | < .01 |
| Acute kidney injury | 49/543 (9.0%) | 11/81 (13.6%) | 38/462 (8.2%) | .139 |
| Acute liver injury | 27/542 (4.9%) | 6/81 (7.4%) | 21/461 (4.5%) | .270 |
| Clinical outcomes | ||||
| Death | 57/584 (9.8%) | 17/84 (20.2%) | 40/500 (8.0%) | .001 |
| Alive | 527/584 (90.2%) | 67/84 (79.8%) | 460/500 (92.0%) |
NA = not available.
Data are shown as n/N (%). P values were calculated by chi-squared test or Fisher's exact test.